December 19, 2017 / 1:12 PM / a year ago

BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By U.S. FDA For Treatment Of Angelman Syndrome

Dec 19 (Reuters) - Ovid Therapeutics Inc:

* OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF ANGELMAN SYNDROME

* OVID THERAPEUTICS INC - EXPANDED ONGOING PHASE 2 STARS CLINICAL TRIAL TO INCLUDE BOTH ADULTS AND ADOLESCENTS WITH ANGELMAN SYNDROME

* OVID THERAPEUTICS INC - EXPECTS DATA FROM STARS TRIAL IN SECOND HALF OF 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below